Denali Therapeutics (NASDAQ:DNLI) Raised to "Strong-Buy" at William Blair

William Blair upgraded shares of Denali Therapeutics (NASDAQ:DNLI - Free Report) to a strong-buy rating in a research note published on Thursday, April 24th,Zacks.com reports.

A number of other equities research analysts have also recently commented on DNLI. Cantor Fitzgerald upgraded Denali Therapeutics from a "neutral" rating to an "overweight" rating in a report on Thursday, April 10th. Oppenheimer lowered their target price on Denali Therapeutics from $50.00 to $42.00 and set an "outperform" rating on the stock in a report on Monday, March 3rd. HC Wainwright increased their target price on Denali Therapeutics from $80.00 to $87.00 and gave the company a "buy" rating in a report on Friday, February 28th. Morgan Stanley started coverage on Denali Therapeutics in a research note on Friday, March 7th. They set an "overweight" rating and a $33.00 price target on the stock. Finally, Robert W. Baird initiated coverage on Denali Therapeutics in a research note on Tuesday, January 7th. They set an "outperform" rating and a $31.00 price objective on the stock. One equities research analyst has rated the stock with a hold rating, fourteen have given a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Denali Therapeutics presently has a consensus rating of "Buy" and a consensus target price of $37.57.

Denali Therapeutics Stock Down 3.0 %

DNLI traded down $0.50 on Thursday, hitting $16.15. 449,317 shares of the company traded hands, compared to its average volume of 1,083,753. The company has a 50 day moving average of $14.66 and a 200-day moving average of $20.65. The stock has a market capitalization of $2.35 billion, a PE ratio of -5.83 and a beta of 1.58. Denali Therapeutics has a 12-month low of $10.57 and a 12-month high of $33.33.

Denali Therapeutics (NASDAQ:DNLI - Get Free Report) last issued its earnings results on Thursday, February 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.75) by $0.08. On average, research analysts anticipate that Denali Therapeutics will post -2.71 EPS for the current year.

Institutional Investors Weigh In On Denali Therapeutics

Large investors have recently added to or reduced their stakes in the stock. KLP Kapitalforvaltning AS acquired a new stake in Denali Therapeutics in the fourth quarter worth $532,000. Proficio Capital Partners LLC acquired a new position in shares of Denali Therapeutics during the fourth quarter valued at $514,000. JPMorgan Chase & Co. increased its holdings in shares of Denali Therapeutics by 6.5% during the third quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company's stock valued at $6,857,000 after purchasing an additional 14,324 shares during the period. Principal Financial Group Inc. increased its holdings in shares of Denali Therapeutics by 13.8% during the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company's stock valued at $36,076,000 after purchasing an additional 149,939 shares during the period. Finally, Vanguard Group Inc. increased its holdings in shares of Denali Therapeutics by 7.6% during the fourth quarter. Vanguard Group Inc. now owns 12,021,230 shares of the company's stock valued at $244,993,000 after purchasing an additional 843,996 shares during the period. 92.92% of the stock is owned by institutional investors and hedge funds.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.